Abstract
Objective To investigate the efficacy and toxicities of gemcitabine and cisplatin as a chemother-apy regimen for patients with advanced non-small cell lung cancer (NSCLC). Methods Thirty-five patients with NSCLC were enrolled in this study. C, emeitabine was given on day 1 and 8 at a dose of 1000 mg/m~2 and cisplatin at a dose of 25 mg/m~2 on day 1 to 3. The chemotherapy was repeated every 28 days, after 2 cycles for evaluating response. Results Complete response (CR), partial response (PR) ,stable disease (SD) and progressive disease (PD) were observed in 0,14,16 and 5 cases, respectively, with a response rate (RR) of 40. 0%. The RR in initial treatment group was found more than that in the retreatment group (52. 2% vs 16.7% ,P<0. 05).The main toxicities were tol-erable, which included myelosuppression, nausea, vomiting, and liver damage. Conclusion Gemcitabine combined with cisplatin is effective and safe in the treatment of NSCLC, especially in the initial treatment patients. Key words: Carcinoma non-small-cell lung cancer; Gemcitabine; Cisplatin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
